Leading science, pioneering therapies
CRM Publications

Improving the translational hit of experimental treatments in multiple sclerosis.

TitleImproving the translational hit of experimental treatments in multiple sclerosis.
Publication TypeJournal Article
Year of Publication2010
AuthorsVesterinen HM, Sena ES, ffrench-Constant C, Williams AC, Chandran S, Macleod MR
JournalMult Scler
Volume16
Issue9
Pagination1044-55
Date Published2010 Sep
ISSN1477-0970
KeywordsAnimals, Behavior, Animal, Bias (Epidemiology), Chi-Square Distribution, Disease Models, Animal, Encephalomyelitis, Autoimmune, Experimental, Endpoint Determination, Humans, Immunologic Factors, Multiple Sclerosis, Reproducibility of Results, Research Design, Sample Size, Time Factors, Translational Medical Research
Abstract

BACKGROUND: In other neurological diseases, the failure to translate pre-clinical findings to effective clinical treatments has been partially attributed to bias introduced by shortcomings in the design of animal experiments.

OBJECTIVES: Here we evaluate published studies of interventions in animal models of multiple sclerosis for methodological design and quality and to identify candidate interventions with the best evidence of efficacy.

METHODS: A systematic review of the literature describing experiments testing the effectiveness of interventions in animal models of multiple sclerosis was carried out. Data were extracted for reported study quality and design and for neurobehavioural outcome. Weighted mean difference meta-analysis was used to provide summary estimates of the efficacy for drugs where this was reported in five or more publications.

RESULTS: The use of a drug in a pre-clinical multiple sclerosis model was reported in 1152 publications, of which 1117 were experimental autoimmune encephalomyelitis (EAE). For 36 interventions analysed in greater detail, neurobehavioural score was improved by 39.6% (95% CI 34.9-44.2%, p

CONCLUSIONS: EAE has proven to be a valuable model in elucidating pathogenesis as well as identifying candidate therapies for multiple sclerosis. However, there is an inconsistent application of measures to limit bias that could be addressed by adopting methodological best practice in study design. Our analysis provides an estimate of sample size required for different levels of power in future studies and suggests a number of interventions for which there are substantial animal data supporting efficacy.

DOI10.1177/1352458510379612
Alternate JournalMult. Scler.
PubMed ID20685763
Grant ListG0800803 / / Medical Research Council / United Kingdom
/ / Medical Research Council / United Kingdom
/ / Wellcome Trust / United Kingdom